Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Calithera Biosciences has raised $10.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2022.
Calithera Biosciences's investors include U.S. Venture Partners, Adage Capital Management, Longwood Fund, Mission Bay Capital, Cystic Fibrosis Foundation.
Calithera Biosciences is headquartered in South San Francisco, United States.
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Calithera Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Calithera Biosciences — Funding & Investors." VCBacked, March 30, 2022, https://www.vcbacked.co/company/calithera-biosciences. Accessed September 30, 2026.
VCBacked. (2022). Calithera Biosciences — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/calithera-biosciences
{{cite web |title=Calithera Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/calithera-biosciences |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated